| Literature DB >> 33803325 |
Saleh Alghamdi1, Ilhem Berrou2, Eshtyag Bajnaid3, Zoe Aslanpour4, Abdul Haseeb5, Mohamed Anwar Hammad1, Nada Shebl4.
Abstract
Antimicrobial stewardship programs (ASPs) in hospitals have long been shown to improve antimicrobials' use and reduce the rates of antimicrobial resistance. However, their implementation in hospitals, especially in developing countries such as Saudi Arabia, remains low. One of the main barriers to implementation is the lack of knowledge of how to implement them. This study aims to explore how an antimicrobial stewardship programme was implemented in a Saudi hospital, the challenges faced and how they were overcome, and the program outcomes. A key stakeholder case study design was used, involving in-depth semi-structured interviews with the core members of the ASP team and analysis of 35 ASP hospital documents. ASP implementation followed a top-down approach and involved an initial preparatory phase and an implementation phase, requiring substantial infectious diseases and clinical pharmacy input throughout. Top management support was key to the successful implementation. ASP implementation reduced rates of multi-drug resistance and prescription of broad-spectrum antimicrobials. The implementation of ASPs in hospital is administrator rather than clinician driven. Outsourcing expertise and resources may help hospitals address the initial implementation challenges.Entities:
Keywords: antimicrobial stewardship programs; hospitals; multi-drug resistance
Year: 2021 PMID: 33803325 PMCID: PMC8000012 DOI: 10.3390/antibiotics10030280
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Patient safety portfolio of programs.
Figure 2Roles and responsibilities of core members of the ASP team. ASP (antimicrobial stewardship programme); ID (Infectious Diseases); DOT (Days of Therapy).
Figure 3The timeline for implementing the ASP in the medical city.
Figure 4ASP implementation process model.
Hospital antibiogram data (2015–2016) showing the percentage of sensitive susceptibilities between specific microorganisms (columns) and antibiotics (rows).
| Microorganisms | |||||||
|---|---|---|---|---|---|---|---|
| Antibiotics | Year |
|
|
|
|
|
|
| Amoxicillin/Clavulanic acid | 2015 | 37 | - | - | - | 28 | - |
| 2016 | 49 | - | - | - | - | - | |
| Cefepime | 2015 | 45 | 28 | 39 | - | - | - |
| 2016 | 48 | 22 | 66 | - | - | - | |
| Ciprofloxacin | 2015 | 33 | 20 | 60 | 20 | 62 | 47 |
| 2016 | 36 | 22 | 75 | 20 | 75 | 69 | |
| Clindamycin | 2015 | - | - | - | 45 | - | |
| 2016 | - | - | - | 28 | 76 | 71 | |
| Colistin | 2015 | - | 69 | - | - | - | - |
| 2016 | - | 97 | - | - | - | - | |
| Gentamicin | 2015 | 71 | 24 | 56 | 46 | 75 | 55 |
| 2016 | 65 | 34 | 79 | 53 | 86 | 71 | |
| Piperacillin/Tazobactam | 2015 | 47 | - | 48 | - | - | - |
| 2016 | 77 | - | 64 | - | - | - | |
Hospital DOT data for July–Dec 2015 (before ASP implementation) and January–June 2016 (after).
| Antibiotics | Total DOT (07–12/2015) | Total DOT (01–06/2016) |
|---|---|---|
| Tigecycline | 1039.8 | 624.5 |
| Colistin | 2080.9 | 1417.2 |
| Meropenem | 2287.2 | 2597.3 |
| Imipenem | 2365.6 | 1666.1 |
| TOTAL | 7773.5 | 6305.1 (−18.9%) |